News

Latest News:

mc2_news-image-icon-07

MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial

POSTED: December 7, 2023

  • MC2-25 CKD is a first-in-class drug candidate and a potential breakthrough in the understanding and treatment of urea associated skin diseases that has puzzled scientists for decades
  • MC2-25 CKD uses a ...

    READ FULL ARTICLE >

mc2_news-image-icon-05

MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus

POSTED: November 23, 2023

  • MC2-25 VLS is a first-in-class drug candidate for urea associated skin diseases using a di-peptide as an iso-cyanate scavenger to inhibit carbamylation of amino acids and proteins in the skin
  • MC2-25 ...

    READ FULL ARTICLE >

mc2_news-image-icon-07

MC2 Therapeutics Announces Positive Phase 2a Results of Novel HSP90 Inhibitor for Hidradenitis Suppurativa Presented at EADV

POSTED: October 11, 2023

  • MC2-32 (RGRN-305) a first in class, oral therapy targeting multiple pathways involved in Hidradenitis Suppurativa (HS) achieves highly positive data in randomized, double-blinded, placebo-controlled trial in 15 patients:
mc2_news-image-icon-07

MC2 Therapeutics Acquires Option to Phase 2 Oral Drug Candidate for Hidradenitis Suppurativa and Other Indications

POSTED: September 25, 2023

  • Option to exclusively license the rights to develop, manufacture and commercialize “RGRN-305” for all human indications, incl. oral treatment of Hidradenitis Suppurativa (“HS”)
  • RGRN-305 is a new chemical entity having a ...

    READ FULL ARTICLE >

mc2_news-image-icon-07

MC2 Therapeutics and Huadong Announce License, Development and Commercialization Agreement for Wynzora® Cream in Greater China

POSTED: August 31, 2023

Copenhagen, Denmark and Hangzhou, China, August 31st, 2023 – MC2 Therapeutics, Ltd (“MC2”), a wholly owned subsidiary of MC2 Therapeutics A/S and Hangzhou Zhongmei Huadong Pharmaceutical Co (“Huadong”), a wholly ...

READ FULL ARTICLE >

MC2 Therapeutics to present at BIO CEO & Investor Conference 2023

POSTED: January 31, 2023

Copenhagen, January 31st, 2023 – MC2 Therapeutics A/S, a commercial stage pharmaceutical company, engaged in research in skin biology and development of novel treatment paradigms for autoimmune and chronic inflammatory ...

READ FULL ARTICLE >

Events:

February 28th - 29th, 2024

MC2 Therapeutics to present at the 17th Annual European Life Sciences CEO Forum

READ MORE >

November 14th - 16th, 2023

Meet MC2 at Jefferies London Healthcare Conference

READ MORE >

May 15th - 16th, 2023

MC2 Therapeutics to present at Bio€quity Europe 2023

READ MORE >

February 7th, 2023

MC2 Therapeutics to present at the BIO CEO & Investor Conference in NYC

READ MORE >

January 9th - 12th, 2023

J.P. Morgan Healthcare Conference 2023 (San Francisco)

READ MORE >

January 8th, 2023

MC2 Therapeutics to present at the Dermatology Summit 2023 in San Francisco

READ MORE >

December 7th, 2022

MC2 Therapeutics to present at Carnegie’s Next Generation Nordic Life Science Champions Seminar 2022

READ MORE >

November 15th - 17th, 2022

MC2 Therapeutics attends the Jefferies London Healthcare Conference

READ MORE >

February 28th, 2022

MC2 exposure at PCMA Business Forum 2022

READ MORE >

August 11th, 2021

MC2 Therapeutics is proud to support National Psoriasis Action Month

READ MORE >

July 23, 2021

MC2 Therapeutics supports World Sjögren’s Day

READ MORE >